Skye Bioscience
SKYE
31 hedge funds and large institutions have $9.91M invested in Skye Bioscience in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 6.29% → 6.04% (-0.25%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
18% less capital invested
Capital invested by funds: $12.1M → $9.91M (-$2.18M)
26% less funds holding
Funds holding: 42 → 31 (-11)
36% less call options, than puts
Call options by funds: $25K | Put options by funds: $39K
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$163K |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$102K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$26.5K |
| 5 |
BlackRock
New York
|
+$3.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$99.6K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$70K |
| 3 |
Two Sigma Investments
New York
|
-$21.2K |
| 4 |
HF
HRT Financial
New York
|
-$20K |
| 5 |
Jane Street
New York
|
-$18.5K |
SKYE Hedge Fund Activity: Q1 2026 in Review
31 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q1 2026, worth a combined $9.91M — down 18% from $12.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SKYE and 4 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Sphera Funds Management, adding an estimated $163K. The largest seller was Millennium Management, cutting an estimated $99.6K.
- 31 institutional investors held Skye Bioscience (SKYE) as of Q1 2026, down from 42 in Q4 2025.
- Funds reported $9.91M of Skye Bioscience stock for Q1 2026, down 18% quarter-over-quarter.
- 4 funds opened new Skye Bioscience positions in Q1 2026 and 14 closed out, a net change of -10 holders.
- The largest Skye Bioscience buyer in Q1 2026 was Sphera Funds Management, an estimated $163K added.
- The largest Skye Bioscience seller in Q1 2026 was Millennium Management, an estimated $99.6K sold.
Based on aggregated 13F filings for Q1 2026.